Copyright © 2001 by the European Society of Cardiology.
The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound
a Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
b Heartcenter Bodensee, Kreuzlingen, Switzerland
c Cardialysis, Rotterdam, The Netherlands
revised January 29, 2001; accepted January 31, 2001
Abstract
Background Studies have reported benefit of oral therapy with the phosphodiesterase inhibitor, trapidil, in reducing restenosis after coronary angioplasty. Coronary stenting is associated with improved late outcome compared with balloon angioplasty, but significant neointimal hyperplasia still occurs in a considerable proportion of patients. The aim of this study was to investigate the safety and efficacy of trapidil 200mg in preventing in-stent restenosis.
Methods Patients with a single native coronary lesion requiring revascularization were randomized to placebo or trapidil at least 1h before, and continuing for 6 months after, successful implantation of a coronary Wallstent. The primary end-point was in-stent neointimal volume measured by three-dimensional reconstruction of intravascular ultrasound images recorded at the 6 month follow-up catheterization.
Results Of 312 patients randomized at 21 centres in nine countries, 303 (148 trapidil, 155 placebo) underwent successful Wallstent implantation, and 139 patients (90%) in the placebo group and 130 (88%) in the trapidil group had repeat catheterization at 26±2 weeks. There was no significant difference between trapidil and placebo-treated patients regarding in-stent neointimal volume (108·6± 95·6mm3vs 93·3±79·1mm3;P=0·16) or % obstruction volume (38±18% vs 36±21%;P=0·32), in angiographic minimal luminal diameter at follow-up (1·63±0·61mm vs 1·74±0·69mm;P=0·17), restenosis rate (31% vs 24%;P=0·24), cumulative incidence of major adverse cardiac events at 7 months (22% vs 20%;P=0·71) or anginal complaints (30% vs 24%;P=0·29).
Conclusion Oral trapidil 600mg daily for 6 months did not reduce in-stent hyperplasia or improve clinical outcome after successful Wallstent implantation and is not indicated for this purpose.
Key Words: Restenosis, stent, trapidil, intravascular ultrasound, quantitative coronary angiography, randomized trial
f1 Correspondence:Prof. P. W. Serruys, Erasmus Medical Center, Thoraxcenter Bd 408, Dr.Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. H. Alvarez, H. M. Kantarjian, and J. E. Cortes Biology of Platelet-Derived Growth Factor and Its Involvement in Disease Mayo Clin. Proc., September 1, 2006; 81(9): 1241 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Lansky, R. A. Costa, G. S. Mintz, Y. Tsuchiya, M. Midei, D. A. Cox, C. O'Shaughnessy, R. A. Applegate, L. A. Cannon, M. Mooney, et al. Non-Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions: Angiographic Follow-Up of the DELIVER Clinical Trial Circulation, April 27, 2004; 109(16): 1948 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. E.J. West, P. N. Ruygrok, C. M.C. Disco, M. W.I. Webster, W. K. Lindeboom, W. W. O'Neill, N. F. Mercado, and P. W. Serruys Clinical and Angiographic Predictors of Restenosis After Stent Deployment in Diabetic Patients Circulation, February 24, 2004; 109(7): 867 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Serruys, M. Degertekin, K. Tanabe, M. E. Russell, G. Guagliumi, J. Webb, J. Hamburger, W. Rutsch, C. Kaiser, R. Whitbourn, et al. Vascular Responses at Proximal and Distal Edges of Paclitaxel-Eluting Stents: Serial Intravascular Ultrasound Analysis From the TAXUS II Trial Circulation, February 10, 2004; 109(5): 627 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Mercado, W Maier, E Boersma, C Bucher, V de Valk, W.W O'Neill, B.J Gersh, B Meier, P.W Serruys, and W Wijns Clinical and angiographic outcome of patients with mild coronary lesions treated with balloon angioplasty or coronary stenting: Implications for mechanical plaque sealing Eur. Heart J., March 2, 2003; 24(6): 541 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Babapulle and M. J. Eisenberg Coated Stents for the Prevention of Restenosis: Part I Circulation, November 19, 2002; 106(21): 2734 - 2740. [Full Text] [PDF]
|
|
|
|
|
|
M. Degertekin, P. W. Serruys, D. P. Foley, K. Tanabe, E. Regar, J. Vos, P. C. Smits, W. J. van der Giessen, M. van den Brand, P. de Feyter, et al. Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation: Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular Ultrasound Follow-Up Circulation, September 24, 2002; 106(13): 1610 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.G. Murphy A monk's prayer: O Lord what is the answer to in-stent restenosis? Commentary on the TRAPIST Study Eur. Heart J., October 2, 2001; 22(20): 1847 - 1849. [PDF]
|
|